Hyperhomocysteinemia in cardiovascular diseases: revisiting observational studies and clinical trials
In conclusion, revisiting observational studies and clinical trials suggests that cardiovascular patients should be screened for hyperhomocysteinemia, when no other risk factor is found. Patients with intermediate/major hyperhomocysteinemia should be properly assessed and treated for vitamin B deficiencies and inherited disorders according to current guidelines. Further trials are needed to assess the lowering homocysteine effect according to hyperhomocysteinemia categories at baseline.PMID:36170884 | DOI:10.1055/a-1952-1946
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Jean-Louis Gueant Rosa-Maria Gueant-Rodriguez Abderrahim Oussalah Stephane Zuily Irwin Rosenberg Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Genetics | Heart | Hematology | Nutrition | Stroke | Study | Thrombosis | Vitamin B | Vitamin B12 | Vitamin B12 Deficiency | Vitamins